A.R.T. Advisors’s Sonoma Pharmaceuticals SNOA Stock Holding History

A.R.T. Advisors’s Portfolio SNOA Stock Details SNOA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-60	Closed	-$15K	–	1617
2018 Q3	$15K	Buy	+60	New	+$21.8K	﹤0.01%	1356

Other funds holding SNOA

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GW & Wade Wellesley, Massachusetts $3.08B AUM 18.99% 1-Year Est. Return

A.R.T. Advisors's SNOA Position: Q4 2018 in Review

A.R.T. Advisors sold out of Sonoma Pharmaceuticals (SNOA) in Q4 2018, closing a stake of 60 shares — an estimated $15K sold.

A.R.T. Advisors first reported a position in SNOA in Q3 2018 and held it in 1 quarter. The position peaked at $15K in Q3 2018. 18 funds tracked by Wall St. Rank hold SNOA as of Q4 2018.

A.R.T. Advisors reported no remaining Sonoma Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
A.R.T. Advisors sold 60 Sonoma Pharmaceuticals shares in Q4 2018, an estimated $15K.
A.R.T. Advisors first reported a position in Sonoma Pharmaceuticals in Q3 2018 and held it in 1 quarter.
A.R.T. Advisors's Sonoma Pharmaceuticals position peaked at $15K in Q3 2018.
18 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q4 2018.

Based on A.R.T. Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.